However, it has also been shown in ovarian cancer and melanoma that 4-1BB expression better identifies tumor-reactive CD8 TILs; 4-1BB+ CD8 TILs responded to peptide stimulation of a HLA-matched cancer cell line, while 4-1BB- CD8 T cells did not [25]. The gene discussed is CD8A; the disease is melanoma.